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Summary RAP-5, a monoclonal antibody raised against a p2l"as peptide, has been claimed to show
immunohistochemical localisation of cells with infiltrative properties in human tumours. We confirmed that
this antibody reveals pronounced cellular heterogeneity in human colonic neoplasms but could find no
obvious relationship to infiltrative activity. RAP-5 bound to many different cell types, neoplastic and normal.
In order to clarify the specificities of RAP-5 we applied it to two cell lines: nontumorigenic hamster
fibroblasts in which ras expression is barely detectable, and a vigorously tumorigenic line derived from these
fibroblasts by insertion of the human mutated Ha-ras oncogene in a high expression vector. Another antibody
to p2l"as, Y13-259, clearly distinguished between these cell lines both on immunoblots and immunocyto-
chemically, but RAP-5 did not. Rather, it bound to proteins of a variety of molecular weights in both cell
lines. The results show that RAP-5 is unlikely to be a useful reagent for detection of ras associated proteins in
human tissues.
Although the mutated form of the human Harvey
ras oncogene was the first transforming gene of
cellular origin to be identified (Der et al., 1982;
Parada et al., 1982; Santos et al., 1982), the precise
role of ras oncogenes in human malignancy is far
from established. Ras genes code for a 21,000
dalton protein, p2lras, which is located on the inner
face of the plasma membrane (Shih et al., 1979;
Willingham et al., 1980, 1983), binds GTP and
possesses GTPase activity (Sweet et al., 1984; Gibbs
et al., 1984; McGrath et al., 1984). Mutations in
the vicinity of codons 12 and 61 of the ras genes
lead to products deficient in GTPase, but not GTP
binding activity, and these products in particular
have been associated with carcinogenesis. Thus,
insertion of mutated ras genes into cultured cells
confers upon them a transformed phenotype and
tumorigenicity in animals (Reddy et al., 1982;
Tabin et al., 1982; Taparowski et al., 1982); mutant
p21ras introduced to cells by micro-injection can
also initiate proliferation and effect transient
phenotypic changes akin to transformation
(Feramisco et al., 1984; Stacey & Kung, 1984); and
ras gene mutation at the critical sites has been
shown to be an early event in experimental
chemical carcinogenesis (Sukumar et al., 1983;
Balmain et al., 1984). In around 15% of human
solid tumours, there is evidence for the presence of
mutated ras genes (reviewed by Weinberg, 1985).
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Amplification of ras genes has also been recorded
in such tumours, although it is rare (Pulciani et al.,
1985). Hyperexpression of ras mRNA, and raised
levels of p2lras (without necessarily implicating
mutation of the gene) have been reported in
primary human tumours in a variety of sites
(Slamon et al., 1984; Spandidos and Agnantis,
1984; Spandidos et al., 1985; Tanaka et al., 1986;
Kurzrock et al., 1986). Some studies suggest that
ras expression increases in parallel with aggressive
behaviour in neoplasms of the human colon (Horan
Hand et al., 1984), breast (Ohuchi et al., 1986) and
prostate (Viola et al., 1986), but the opposite result
has also been reported (Spandidos & Kerr, 1984;
Gallick et al., 1985; Williams et al., 1985; Kerr et
al., 1986).
Recently, a series of monoclonal antibodies
termed RAP1-5 has been raised against a synthetic
peptide, consisting of amino acids 10 - 17 of
mutated humans Ha-ras p21. In immuno-
histochemical studies, these antibodies were claimed
to show striking preferential localisation to
infiltrative carcinoma cells, as compared to non-
infiltrative neoplasms and normal tissues. In this
paper, we examine the reactivity of RAP-5 with a
range of normal and pathological human tissues,
and with rodent cells lines in which widely
divergent levels of expression of human Ha-ras p21
had been achieved through genetic manipulation
(Spandidos & Wilkie, 1984). We have found these
cell lines, together with comparison with another
antibody (Y13-259) of proven specificity to p2lras
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(Furth et al., 1982; Lacal & Aaronson, 1986), to be
particularly helpful in assessing the important
claims made for this new antibody.
Materials and methods
Fibroblast cell lines
CHL and FHO5Tl were maintained in vitro as
described previously (Spandidos & Wilkie, 1984).
CHL cells were originally obtained by culture of
fibroblasts from Chinese hamster lung. FH05TI
cells were derived from CHL cells by transfection
with the plasmid pHO5Tl, which contains the
mutated human Ha-ras (T24 bladder carcinoma cell
line) oncogene adjacent to the SV40 transcriptional
enhancer sequence. Cytocentrifuge preparations
were made from these cells after disruption of the
monolayers by gentle treatment with EDTA and
trypsin.
Human colorectal tissues
Tissues were obtained within minutes of surgical
removal. Some portions were immediately frozen in
liquid nitrogen and stored at -80°C prior to
preparation of cryostat sections, whilst others were
fixed in 4% neutral buffered formaldehyde at room
temperature for processing in paraffin. In all,
frozen material was studied from normal colonic
mucosa (5 cases), colorectal adenomas (6) and
adenocarcinomas (6). Material from the 6 adeno-
carcinomas was also processed in paraffin. For
comparison, formaldehyde fixed paraffin processed
material representing other normal and pathological
tissues was selected from departmental files: tonsil
(1), intradermal naevus (1), malignant melanoma of
skin (1), and bronchial carcinoid tumour (1).
Immunocytochemistry
Immunocytochemical analysis with RAP-5 and
Y13-259 was carried out on 5,um cryostat sections
fixed for 15min in either 4% neutral buffered
formaldehyde or acetone, using a streptavidin-
biotin immunoperoxidase method as described
previously (Williams et al., 1985). With RAP-5, the
same techniques were also applied to dewaxed,
rehydrated paraffin sections. Briefly, sections or
cytocentrifuge preparations were washed in Tris
buffered saline, (TBS - sodium chloride 150mm,
Tris HCl 10mm, pH 7.6) and nonspecific binding
blocked by application of 10% normal rabbit serum
in TBS (NR-TBS). The primary antibody was
applied for 30min at room temperature at the
optimum dilution in NR-TBS. For RAP-5 this
dilution lay between 1:10,000 and 1:20,000, whilst
for Y13-259 the optimum dilution for use with
tissue sections was 1:100 and with cytocentrifuge
preparations 1:500. The sections were washed in
TBS, and incubated for 30min at room temperature
in the second antibody. For RAP-5, this was sheep
anti-mouse immunoglobulin (Amersham Inter-
national) and for Y13-259 goat anti-rat immuno-
globulin (Sigma), both biotinylated and diluted
1:50 in NR-TBS. After further washing in TBS
the sections were incubated for 15min with
streptavidin-biotinylated horseradish peroxidase
complex (Amersham) diluted 1:200 in NR-TBS.
The reaction was developed after a final wash in
TBS, with diaminobenzidine solution (1 mgml-1)
(BDH) in 50mM Tris HCl pH7.6, containing 10mM
imidazole activated immediately prior to use with
H202' The sections were briefly counterstained with
haematoxylin, dehydrated and mounted.
Negative controls were included for each case,
consisting of sections treated identically to the
others but with NR-TBS replacing the primary
antibody. Invariably, these gave no immuno-
peroxidase reaction save over macrophages and
polymorphonuclear leukocytes within the tissues.
Immunoblots
These were prepared from lysates of CHL and
FHO5T1 cells. Washed cell pellets were lysed in
100mM sodium chloride, 10mM Tris pH7.5, 0.1%
SDS, 1% NP40 at 40C. Insoluble residue was
removed by centrifugation at 30,000g for 30min
and the supernatants were denatured by heat im-
mediately prior to electrophoresis. Approximately
20jug of protein was loaded per track on 15%
polyacrylamide gels, blotted on nitrocellulose, and
detected by Indian ink (Hancock & Tsung, 1983),
or immunostaining. We used essentially the same
conditions for immunostaining of the nitrocellulose
filter as for the cytological preparations, with the
exception that the antibody dilutions used were
1:100 and 1:1000 for both Y13-259 and RAP-5.
Incubation was for 2h at room temperature.
Results
Binding ofRAP-5 and Y13-259 to human tissue
sections
We confirmed, in the present series of experiments,
our previous results on the staining pattern of Y13-
259 on acetone-fixed frozen sections of human
colorectal tissues. Normal mucosa and the
epithelium of most adenocarcinomas showed low
levels of reactivity, whilst in general adenomas
showed staining of greater intensity. We did not
observe specific staining in nonepithelial cell types.EVALUATION OF AN ANTIBODY TO RAS PEPTIDE 879
RAP-5, applied to formaldehyde-fixed frozen
sections of the same and other blocks showed a
different pattern: although normal epithelium
tended to stain at low levels, there were no
consistent differences between infiltrative and non-
infiltrative neoplasms. Infiltrative carcinomas some-
times showed a moderate reaction, but sometimes
were negative, whilst non-infiltrative lesions also
gave positive reactions. Within individual tumours
there was considerable variation in the distribution
of positively staining cells, and in the intensity of
the reaction (Figure la,b). We frequently observed
moderate staining of the muscularis propria.
Serosal mesothelium also consistently gave a strong
reaction. In formaldehyde-fixed paraffin and frozen
sections of a variety of other tissues, RAP-5 gave
strongly positive reactions, notably in the cells of
an intradermal naevus, malignant melanoma, and
carcinoid tumour, but there was no obvious
relationship with aggressive activity (Figure 2a-c).
Although only single cases of these conditions were
studied, the results indicate that reactivity to RAP-5
is not restricted to epithelial cells or to cells
originating from any one germ layer.
Figure 1 Immunoperoxidase detection of RAP-5
binding to formaldehyde fixed paraffin sections of
human colonic adenoma (a) and infiltrative colonic
carcinoma (b). Heterogeneity of cellular staining is
evident in both the benign and malignant tumour.
( x 50,a; x 160,b).
Binding ofRAP-S and Y13-259 to proteins in
ras-expressing cell lines
As previously reported (Williams et al., 1985),
Y13-259 applied to acetone fixed cytocentrifuge
preparations of the ras-transformed cell line
FHOSTI, yielded strong immunochemical staining
over all cells (Figure 3a), whereas less than 5% of
the parental, untransformed CHL fibroblasts gave
positive reactions. Analysis of the antibody binding
proteins on immunoblots, after SDS-polyacrylamide
gel electrophoresis, confirmed that Y13-259 at both
1: 100 and 1: 1000 dilution detected a single protein,
of apparent mol. wt 21 kd in FHO5TI cells (Figure
4a). In extracts of CHL cells the same binding
protein was either undetectable or present in much
reduced quantity. Indian ink staining of the
nitrocellulose blots, or staining of unblotted poly-
acrylamide gels with kenacid blue showed that in
terms of proteins identifiable by these means the
extracts from FHOSTI and CHL cells were closely
similar.
In contrast with these results, immunocyto-
chemistry using RAP-5 as the primary antibody
revealed no differences between the CHL and
FHOST1 cells (Figure 3b,c). All cells of either type
were negative after acetone fixation, but after
fixation in formaldehyde gave strongly positive
staining over a wide range of dilutions down to
1:20,000. Analysis of the antibody binding proteins
was attempted on immunoblots. At dilutions of
1: 1000 RAP-S scarcely defined discrete protein
bands in gel tracks loaded with extracts of either
CHL or FHOSTI cells (Figure 4b). At tenfold
higher concentration, a number of proteins of a
wide range of molecular size appeared to bind to
the antibody; the majority of these were present in
similar quantity in FHOSTI and CHL extracts
(Figure 4c).
Discussion
RAP-S is secreted by a hybridoma derived from
spleen cells of a mouse immunised with a ras
octapeptide linked to thyroglobulin (Horan Hand et
al., 1984). The octapeptide had the amino acid
sequence 10 - 17 of the mutated human (T24) Ha-
ras p21, and selection of the hybridoma was based
upon preferential binding of its immunoglobulin to
the mutated as opposed to the non-mutated
peptide. In practice, however, RAP-5 was found by
its originators to detect epitopes present in a far
higher proportion of human tumours than are
associated with transforming mutations of the ras
gene family. It was assumed that cross-reaction
with non-mutated p21 was responsible. Specificity
of RAP-5 for p21 ras was adduced from880 A. ROBINSON et al.
(b)
Figure 2 Immunoperoxidase detection of RAP-5 binding to formaldehyde fixed paraffin sections of human
intradermal naevus (a), malignant melanoma of skin (b), and bronchial carcinoid tumour (c). The naevus and
tumour cells show positive staining, with some heterogeneity, and positive cells are also identified in the
overlying epidermis (a & b) or respiratory epithelium (c). ( x 160).EVALUATION OF AN ANTIBODY TO RAS PEPTIDE 881
Figure 3 Positive staining of cytocentrifuged FH05T1 cells by Y13-259 (a). Similarly treated CHL cells
consistently gave no staining. In contrast, both FHO5T1 cells (b) and CHL cells (c) showed positive staining
with RAP-5. (x 160).
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Figure 4 Electrophoresis of proteins from FHO5T1
(F) and CHL cells (C). In (a), an immunoblot stained
with Y13-259 at 1:100 dilution, a single band of 21 Kd
appears in the FH05T1 extract, but is absent from the
CHL extract. RAP-5 staining of a blot of identical
extracts, at 1:1000 dilution (b) or 1:100 dilution (c)
showed multiple reactive proteins in both FHO5T1 and
CHL cells. For comparison, similarly loaded tracks in
the original polyacrylamide gel, stained with kenacid
blue, are shown (d) with the position of 14Kd and
24Kd marker proteins (-*).
competition binding studies and from immunoblots,
although the concentrations of antibody used in the
latter were unexpectedly high. Published data on
RAP-5 do not yet include studies on a wide range
of neoplastic and normal tissues. The major interest
in this new antibody derived from the observation
that it detected heterogeneity within human breast,
colonic and prostatic neoplasms, preferentially
staining areas showing infiltration of adjacent
tissues, provided it was applied to sections fixed in
formaldehyde (Horan Hand et al., 1984; Thor et
al., 1984; Viola et al., 1985, 1986; Ohuchi et al.,
1986). There were obvious implications of great
fundamental and practical importance in this
suggestion.
The data presented in this paper demonstrate the
value of unequivocal biological test systems for
such novel and potentially exciting reagents.
FHO5TI cells and the parental CHL fibroblast line
differ from one another in the possession of a
mutated Ha-ras gene, in expression of the gene at
the level of transcription (a feature which we
confirmed in dot blots of RNA extracted from cells
of similar passage history to those described here),
in expression of a protein with the molecular size
expected of p2lras, in availability of this protein for
detection by immunocytochemical methods, and in
the ability to generate rapidly growing aggressive
tumours in immune suppressed animals (Spandidos
& Wilkie, 1984; Spandidos, 1985). A reagent
capable of distinguishing aggressive from non-
infiltrative cells on the basis of ras expression ought
to discriminate between these two cell lines, but
RAP-5 did not. Rather, under the conditions
r vW 9:882 A. ROBINSON et al.
described by its originators, it seemed to detect
proteins plentiful in both cells, and also in many
human cell types, both normal and neoplastic, of a
variety of embryological derivations. These results
do not exclude the possibility that RAP-5 may bind
to a ras peptide, but indicate that it also recognises
other widely distributed epitopes which are not
related to ras expression. A similar conclusion has
recently been reached on the basis of immunohisto-
chemical studies on human breast tissue (Ghosh et
al., 1986). Other antibodies raised against small
oncogene peptides have been shown in the past to
be capable of reaction with epitopes common to
many cellular proteins despite the appearances of
specificity in immunoabsorption studies (Nigg et
al., 1982).
The role of ras products in tumour aggression
remains undecided. In experimental animals, cells
transformed by the mutated ras gene have been
shown to be capable of both infiltration and
metastasis (Spandidos & Wilkie, 1984; Muschel et
al., 1985; Thorgeirsson et al., 1985), but ras
expression does not always confer aggressive
properties. Normal ras genes are expressed physio-
logically in non-dividing tissues (Spandidos &
Dimitrov, 1985), and in one phaeochromocytoma
cell line insertion of the products of the mutated ras
gene led to differentiation and replication arrest
(Bar-Sagi & Feramisco, 1985). Several different
groups have presented evidence from animal
tumours and human colonic neoplasia that
activation (by mutation or hyperexpression) of the
ras gene is a feature of early rather than late
neoplasia (Sukumar et al., 1983; Balmain et al.,
1984; Williams et al., 1985; Yuspa et al., 1985).
It seems probable that immunohistochemical
methods will remain important in attempts to
clarify the role of ras and other oncogenes in
human neoplasia. This paper highlights the value of
genetically modified cell lines in the critical
evaluation of antibodies raised against oncogene
proteins and peptides, and in particular casts
serious doubt on the usefulness of RAP-5 in
detection of human ras-coded, or ras-associated
proteins.
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